Comparison of Side Effects Between 3‐Monthly and 1‐Monthly Paliperidone Palmitate Formulations in Patients With Schizophrenia
In this within-patient cohort stabilized on PP1M, conversion to PP3M was not associated with an increase in overall UKU side-effect burden. Selecting the appropriate dose before switching and preferring monotherapy may enhance treatment comfort. These results may help guide clinicians in selecting long-acting injectable antipsychotics in practice.
Authors
- Bengü Yücens (ORCID: https://orcid.org/0000-0002-4721-7288)
- Erkan Kuru
- M. Hakan Türkçapar
- Ilker Ozdemir
Institutions
- Ankara University (TR)
- Bursa Technical University (TR)
- Psychiatric Association of Turkey (TR)
- Turkish Thoracic Society (TR)
- S.B.Ü. Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi (TR)
- Pamukkale University (TR)
Publication Details
- Journal
- Human Psychopharmacology Clinical and Experimental
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1002/hup.70033
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00